Phase 2 study for people with Lupus

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor AstraZeneca
Registry number NCT06897930
Started 21 April 2025 Today 16 October 2026 Estimated completion 1 May 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Darlinghurst NSW Recruiting
Research Site Melbourne VIC Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 70 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 150

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

INCLUSION:

1. Males or females aged 18 through 70 years inclusive at the time of consent.

2. Written informed consent in accordance with federal, local, and institutional guidelines.

3. Must be able and willing to adhere to the study visit schedule and other protocol requirements

4. Adequate hepatic, renal, pulmonary, and cardiac function

5. Have a clinical diagnosis of SLE according to the EULAR/ American College of Rheumatology (ACR) 2019 criteria with a positive ANA ≥1:80 and a score ≥10.

6. Have used at least two standard immunosuppressants (including one biological agent).

7. SLEDAI-2K score ≥6 at screening.

8. Must include a significant SLE related organ involvement: arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, vasculitis, or renal.

9. For lupus nephritis: Diagnosis of proliferative lupus nephritis based on a renal biopsy obtained within 6 months prior to signing the informed consent form or during the screening period Class III, IV or V LN according to the WHO 2003 ISN/RPS classification.

EXCLUSION:

1. Have received prior treatment with CAR T therapy directed at any target.

2. Have received any therapy that is targeted to CD19 and/or BCMA

3. Received allogenic stem cell transplant or autologous stem cell transplant.

4. An active malignancy that is progressing or requires active treatment.

5. Primary immunodeficiency

6. Active viral or bacterial infection

Dates on the record

Started 21 April 2025
Estimated completion 1 May 2029
Registry last updated 10 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 10 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.